Nurix Therapeutics Inc (NRIX) Directors and Executive Officers

Officers & Directors

1. Arthur T. Sands, M.D., Ph.D. - President, Chief Executive Officer, and Director (Principal Executive Officer)
Dr. Sands has over 30 years of experience in the biopharmaceutical industry, focusing on drug discovery, development, and commercialization. Prior to founding Nurix Therapeutics, he served as Chief Scientific Officer at Lexicon Pharmaceuticals, Inc. and held various senior management positions at Tularik Inc.

2. Paul M. Silva - Director

3. Hans Van Houte - Chief Financial Officer (Principal Financial and Accounting Officer)

4. Lori A. Kunkel - Director

5. Edward C. Saltzman - Director

6. Judith A. Reinsdorf - Director

7. David L. Lacey - Chairman and Director

8. Julia P. Gregory - Director ,

Nurix Therapeutics Inc currently has 317 employees.

News about Nurix Therapeutics Inc Key Personnel

Nurix Therapeutics Charts Ambitious Path Amid Financial Challenges and Promising Pipeline

In a significant strategic update, Nurix Therapeutics Inc. has laid out its ambitious goals for 2025, focusing on advancing its robust pipeline targeted at revolutionizing treatment for cancer and autoimmune diseases. One of the highlights of this plan includes the initiation of a suite of clinical trials aimed at supporting the global registration of NX-5948, a therapeutic candidate positioned to tackle chronic lymphocytic leukemia (CLL). This decision reflects the company s commitment to progressing potentially transformative treatments even as it navigates substantial financial headwinds.Despite these substantial efforts to innovate in the biotech arena, Nurix’s financial results tell a contrasting stor...

Nurix Therapeutics Faces Financial Challenges Amid Advances in Targeted Protein Modulation for Cancer and Autoimmune Diseases

Nurix Therapeutics, a biopharmaceutical company focused on targeted protein modulation for the treatment of cancer and autoimmune diseases, has recently outlined its 2024 strategic priorities. The company plans to advance its pipeline and prioritize the enrollment acceleration of NX-5948 for leukemia and lymphoma based on positive Phase 1 data. However, behind these ambitious goals, Nurix faces significant financial challenges, as it reported a cumulative net loss of $-149 million during the 12 months ending in the third quarter of 2023, resulting in a negative return on investment (ROI) of -50.56%.
Nurix s Strategic Priorities and Promising Developments:
Nurix Therapeutics has made signifi...